evidence table
Glucosamine Knee Pain Meta-Analysis Evidence Table
Structured evidence table for Glucosamine Knee Pain Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Glucosamine Knee Pain Meta-Analysis | , , d d N Figure Chondroitin sulfate (CS) is an anionic, sulfated glycosaminoglycan found in various connective tissues, including cartilage, bone, ligaments, tendons, and skin. | 3 | Silva Vitor Alfredo de Santana (2025) | Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges |
| Glucosamine Knee Pain Meta-Analysis | In terrestrial animals, it is predominantly found as monosulfated disaccharides at the 4-O or 6-O positions of GalNAc (CS-A and CS-C, respectively), along with a small percentage of nonsulfated disaccharides (CS-0). | 3 | Silva Vitor Alfredo de Santana (2025) | Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges |
| Glucosamine Knee Pain Meta-Analysis | While foundational and pioneering studies are acknowledged, particular emphasis is placed on the most recent evidence to capture the current state of knowledge, clarify ongoing controversies, and highlight the latest therapeutic advances. | 3 | Silva Vitor Alfredo de Santana (2025) | Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges |
| Glucosamine Knee Pain Meta-Analysis | Osteoarthritis (OA) is a highly prevalent musculoskeletal rheumatic disorder that significantly impacts individual health, healthcare systems, and overall socioeconomic costs.OA remains a substantial global health burden: in 2020, an estimated 595 million people (≈7.6% of the global population) had OA, representing a 132.2% increase in cases since 1990. | 3 | Silva Vitor Alfredo de Santana (2025) | Impact of Symptomatic Slow-Acting Drugs on Inflammatory Pathways in Osteoarthritis: Therapeutic Advances and Future Challenges |
| Glucosamine Knee Pain Meta-Analysis | To ensure a robust synthesis of evidence, we conducted a systematic search of PubMed, Embase, and Web of Science (2020-2025) for high-quality clinical trials, meta-analyses, and guidelines. | 4 | Wang H (2026) | Evolving Strategies for Knee Osteoarthritis: A Narrative Review of Integrated Rehabilitation, Pharmacologic, and Joint-Preserving Interventions. |
| Glucosamine Knee Pain Meta-Analysis | This narrative review evaluates the clinical transition from reactive, surgery-centric models to a proactive, integrated framework to mitigate the profound socioeconomic burden and functional decline associated with the disease. | 4 | Wang H (2026) | Evolving Strategies for Knee Osteoarthritis: A Narrative Review of Integrated Rehabilitation, Pharmacologic, and Joint-Preserving Interventions. |
| Glucosamine Knee Pain Meta-Analysis | We synthesized evidence across non-pharmacological rehabilitation, pharmacotherapy, and advanced joint-preserving surgeries, emphasizing optimal intervention windows and stage-specific mechanobiological requirements. | 4 | Wang H (2026) | Evolving Strategies for Knee Osteoarthritis: A Narrative Review of Integrated Rehabilitation, Pharmacologic, and Joint-Preserving Interventions. |
| Glucosamine Knee Pain Meta-Analysis | Knee osteoarthritis (KOA) is a primary driver of global disability, currently affecting over 365 million adults, with projections suggesting a 74.9% increase by 2050. | 4 | Wang H (2026) | Evolving Strategies for Knee Osteoarthritis: A Narrative Review of Integrated Rehabilitation, Pharmacologic, and Joint-Preserving Interventions. |
Source documents